Lipid-lowering effects of time-released garlic powder tablets in double-blinded placebo-controlled randomized study

Journal of Atherosclerosis and Thrombosis

Volumn 15, Issue 6, 2008, Pages 334-338

  Sobenin, Igor A ^a,b   Andrianova, Irina V ^b   Demidova, Olga N ^c   Gorchakova, Tatiana V ^a,b   Orekhov, Alexander N ^a,d  

^a INSTITUTE OF GENERAL PATHOLOGY AND PATHOPHYSIOLOGY   (Russian Federation)

^b INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^c State Medical Academy   (Russian Federation)

^d Institute of Chemical Problems of Ecology   (Russian Federation)

Author keywords

Allicor; Garlic; Hypercholesterolemia; Placebo controlled trial

Indexed keywords

ALLICOR; ANTILIPEMIC AGENT; CHOLESTEROL; GARLIC EXTRACT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; UNCLASSIFIED DRUG; LIPID; PLANT EXTRACT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; GARLIC; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; MALE; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; TABLET FORMULATION; TIMED DRUG RELEASE; TREATMENT DURATION; BLOOD; CHEMISTRY; METABOLISM; MIDDLE AGED; POWDER; TABLET; TREATMENT OUTCOME;

ADULT; AGED; CHOLESTEROL, HDL; DOUBLE-BLIND METHOD; GARLIC; HUMANS; HYPERCHOLESTEROLEMIA; LIPIDS; MALE; MIDDLE AGED; PLACEBOS; PLANT EXTRACTS; POWDERS; TABLETS; TREATMENT OUTCOME;

EID: 59149090637     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.E550     Document Type: Article

References (29)

1. Kannel WB, Neaton JD, Wentworth D, Thomas HE, Stamler J, Hulley SB, Kielsberg MO: Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT. Multiple Risk Factor Intervention Trial. Am Heart J, 1986; 112:825-836
2. Donnell CJ, Kannel WB: Cardiovascular risks of hypertension: lessons from observational studies. J Hypertens Suppl, 1998; 16:3-7
3. Anderson KM, Odell PM, Wilson PW, Kannel WB: Cardiovascular disease risk profiles. Am Heart J, 1991; 121:293-298
4. Kannel WB, Castelli WP, Gordon T: Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann Intern Med, 1979; 90:85-91
5. Bordia AK, Joshi HK, Sanadhya YK, Bhu N: Effect of essential oil of garlic on serum fibrinolytic activity in patients with coronary artery disease. Atherosclerosis, 1977; 28:155-159
6. Lau B, Lam F, Wang-Chen R: Effect of odor-modified garlic preparation on blood lipids. Nutr Res, 1987; 7:139-149
7. Harenberg J, Giese C, Zimmermann R: Effect of dried garlic on blood coagulation, fibrinolysis, platelet aggregation and serum cholesterol levels in patients with hyperlipoproteinemia. Atherosclerosis, 1988; 74:247-249
8. Phelps S, Harris WS: Garlic supplementation and lipoprotein oxidation susceptibility. Lipids, 1993; 28:475-477
9. Rahman K: Historical perspective on garlic and cardiovascular disease. J Nutr, 2001; 131:977S-979S
10. Shepherd J, Barter P: Lipid-lowering - translating evidence into benefits. Atheroscler Suppl, 2002; 2:1-3
11. Shepherd J: A tale of two trials: The West of Scotland Coronary Prevention Study and the Texas Coronary Atherosclerosis Prevention Study. Atherosclerosis, 1998; 139:223-229
12. Stavric B: Role of chemopreventers in human diet. Clin Biochem, 1994; 27:319-332
13. Agarwal KC: Therapeutic actions of garlic constituents. Med Res Rev, 1996; 16:111-124
14. Ali M, Thompson M: Consumption of a garlic clove a day could be beneficial in preventing thrombosis. Prostaglandins Leukot Essent Fatty Acids, 1995; 53:211-212
15. Reuter HD, Koch HP, Lawson LD: Therapeutic effects of garlic and its preparations. In: Koch HP, Lawson LD, eds. Garlic. London, UK, Williams and Wilkins, 1996; 135-162
16. Steiner M, Khan AH, Holbert D, Lin RI: A double-blind crossover study in moderately hypercholesterolemic men that compared the effect of aged garlic extract and placebo administration on blood lipids. Am J Clin Nutr, 1996; 64:866-870
17. Morcos NC: Modulation of lipid profile by fish-oil and garlic combination. J Natl Med Assoc, 1997; 89:673-678
18. Simons LA, Balasubramaniam S, von Konigsmark M, Parfitt A, Simons J, Peters W: On the effect of garlic on plasma lipids and lipoproteins in mild hypercholesterolaemia. Atherosclerosis, 1995; 113:219-225
19. Silagy C, Neil A: Garlic as a lipid lowering agent - a meta-analysis. J R Coll Physicians Lond, 1994; 28:39-45
20. Neil HA, Silagy CA, Lancaster T, Hodgeman J, Vos K, Moore JW, Jones L, Cahill J, Fowler GH: Garlic powder in the treatment of moderate hyperlipidaemia: a controlled trial and meta-analysis. J R Coll Physicians Lond, 1996; 30:329-334
21. Isaacsohn JL, Moser M, Stein EA, Dudley K, Davey JA, Liskov E, Black HR: Garlic powder and plasma lipids and lipoproteins: a multicenter, randomized, placebo-controlled trial. Arch Intern Med, 1998; 158:1189-1194
22. Berthold HK, Sudhop T: Garlic preparations for prevention of atherosclerosis. Curr Opin Lipidol, 1998; 9:565-569
23. Lawson LD, Ransom DK, Hughes BG: Inhibition of whole blood platelet-aggregation by compounds in garlic clove extracts and commercial garlic products. Thromb Res, 1992; 65:141-156
24. Newall CA, Anderson LA, and Phillipson JD: Garlic. In: Newall CA, Anderson LA, Phillipson JD, eds. Herbal Medicines - A Guide for Health Care Professionals. Cambridge, UK: University Press, 1995; 129-133
25. Iberl B, Winkler G, Müller B, Knobloch K: Quantitative Determination of Allicin and Alliin from Garlic by HPLC*. Planta Med, 1990; 56:320-326
26. Amagase H, Petesch BL, Matsuura H, Kasuga S, Itakura Y: Intake of garlic and its bioactive components. J Nutr, 2001; 131:955S-962S
27. Orekhov AN, Tertov VV, Sobenin IA, Pivovarova EM: Direct anti-atherosclerosis-related effects of garlic. Ann Med, 1995; 27:63-65
28. Orekhov AN: New prospects for the treatment of atherosclerosis: garlic preparations. Ter Arkh, 1998; 70:75-78
29. Andrianova IV, Ionova VG, Demina EG, Shabalina AA, Karabasova IaA, Liutova LI, Povorinskaia TE, Orekhov AN: Use of allikor for the normalization of fibrinolysis and hemostasis in patients with chronic cerebrovascular diseases. Kim Med (Mosk), 2001; 79:55-58